abstract |
The application describes the use of (I) EtxB, CtxB or VtxB not containing complete toxin; (Ii) an agent other than EtxB or CtxB with GM1-binding activity, or an agent other than VtxB with Gb3-binding activity, or (iii) an agent that affects intracellular signals mediated by GM1 binding or Gb3 binding, as an immunomodulator for a vaccine intended for active prophylaxis of infectious diseases. |